JPH08509957A - デオキシヌクレオチド合成の阻害剤を使用することによって逆転写酵素依存ウイルスの複製を阻害する新規な方法 - Google Patents
デオキシヌクレオチド合成の阻害剤を使用することによって逆転写酵素依存ウイルスの複製を阻害する新規な方法Info
- Publication number
- JPH08509957A JPH08509957A JP6518466A JP51846694A JPH08509957A JP H08509957 A JPH08509957 A JP H08509957A JP 6518466 A JP6518466 A JP 6518466A JP 51846694 A JP51846694 A JP 51846694A JP H08509957 A JPH08509957 A JP H08509957A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cells
- replication
- compound
- hydroxyurea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 230000015572 biosynthetic process Effects 0.000 title claims description 24
- 238000003786 synthesis reaction Methods 0.000 title claims description 20
- 239000003112 inhibitor Substances 0.000 title claims description 16
- 230000029812 viral genome replication Effects 0.000 title description 14
- 230000002441 reversible effect Effects 0.000 title description 2
- 229960001330 hydroxycarbamide Drugs 0.000 claims abstract description 104
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims abstract description 103
- 210000004027 cell Anatomy 0.000 claims abstract description 88
- 241000700605 Viruses Species 0.000 claims abstract description 62
- 230000010076 replication Effects 0.000 claims abstract description 54
- 239000003814 drug Substances 0.000 claims abstract description 53
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- 230000003834 intracellular effect Effects 0.000 claims abstract description 30
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 28
- 235000021317 phosphate Nutrition 0.000 claims abstract description 28
- 102100034343 Integrase Human genes 0.000 claims abstract description 27
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims abstract description 27
- 230000001419 dependent effect Effects 0.000 claims abstract description 26
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 18
- 239000010452 phosphate Substances 0.000 claims abstract description 18
- 108020005202 Viral DNA Proteins 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 239000005549 deoxyribonucleoside Substances 0.000 claims abstract description 10
- 210000004102 animal cell Anatomy 0.000 claims abstract description 9
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims abstract description 9
- 230000002950 deficient Effects 0.000 claims abstract description 7
- 108020004414 DNA Proteins 0.000 claims description 48
- 239000002777 nucleoside Substances 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 22
- 230000000840 anti-viral effect Effects 0.000 claims description 21
- -1 nucleoside phosphate analog Chemical class 0.000 claims description 20
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 19
- 241001430294 unidentified retrovirus Species 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 230000007442 viral DNA synthesis Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 230000000779 depleting effect Effects 0.000 claims description 5
- 102000004316 Oxidoreductases Human genes 0.000 claims description 4
- 108090000854 Oxidoreductases Proteins 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims description 3
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims description 3
- 230000002028 premature Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 51
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 72
- 210000000265 leukocyte Anatomy 0.000 description 45
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 40
- 238000011282 treatment Methods 0.000 description 33
- 208000015181 infectious disease Diseases 0.000 description 32
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 24
- 101710205625 Capsid protein p24 Proteins 0.000 description 17
- 101710177166 Phosphoprotein Proteins 0.000 description 17
- 101710149279 Small delta antigen Proteins 0.000 description 17
- 230000006820 DNA synthesis Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 210000002540 macrophage Anatomy 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 16
- 208000030507 AIDS Diseases 0.000 description 15
- 241000700721 Hepatitis B virus Species 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 150000003833 nucleoside derivatives Chemical class 0.000 description 15
- 229960002555 zidovudine Drugs 0.000 description 14
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 14
- 208000031886 HIV Infections Diseases 0.000 description 11
- 241000282412 Homo Species 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 239000003443 antiviral agent Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 229940127073 nucleoside analogue Drugs 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 208000037357 HIV infectious disease Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 102100020873 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 102000018146 globin Human genes 0.000 description 4
- 108060003196 globin Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 241000701489 Cauliflower mosaic virus Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000714165 Feline leukemia virus Species 0.000 description 3
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000001177 diphosphate Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000002250 progressing effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000002342 ribonucleoside Substances 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- AJKVQEKCUACUMD-UHFFFAOYSA-N 2-Acetylpyridine Chemical compound CC(=O)C1=CC=CC=N1 AJKVQEKCUACUMD-UHFFFAOYSA-N 0.000 description 1
- OKQHSIGMOWQUIK-UHFFFAOYSA-N 2-[(2-aminopurin-9-yl)methoxy]ethanol Chemical compound NC1=NC=C2N=CN(COCCO)C2=N1 OKQHSIGMOWQUIK-UHFFFAOYSA-N 0.000 description 1
- MYYGWTHTRXMJJX-UHFFFAOYSA-N 2-amino-1-hydroxyguanidine Chemical class N\N=C(\N)NO MYYGWTHTRXMJJX-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N 2-amino-9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- 241000640643 Adenes Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 102000016903 DNA Polymerase gamma Human genes 0.000 description 1
- 108010014080 DNA Polymerase gamma Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 240000001973 Ficus microcarpa Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- 208000031957 HIV carrier Diseases 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N-3,4-tridhydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 description 1
- 101000986396 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Poly(A) RNA polymerase protein 2 Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102100034939 Terminal nucleotidyltransferase 4A Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- QSJHJRZQRKIPOJ-UHFFFAOYSA-N acetamide 1,2-dihydropyrimidine Chemical compound C(C)(=O)N.N1CN=CC=C1 QSJHJRZQRKIPOJ-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- JOAASNKBYBFGDN-UHFFFAOYSA-N chembl1214554 Chemical compound ON=C(N)C1=CC=C(O)C(O)=C1 JOAASNKBYBFGDN-UHFFFAOYSA-N 0.000 description 1
- LJHGXGDHNOZLFT-XCVCLJGOSA-N chembl331656 Chemical compound N\C(S)=N\N=C\C1=CC=C(O)C=N1 LJHGXGDHNOZLFT-XCVCLJGOSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- FTDHDKPUHBLBTL-SHYZEUOFSA-K dCDP(3-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 FTDHDKPUHBLBTL-SHYZEUOFSA-K 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- FRQISCZGNNXEMD-QPPQHZFASA-N gemcitabine diphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 FRQISCZGNNXEMD-QPPQHZFASA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- ISIUXVGHQFJYHM-UHFFFAOYSA-N isoquinolin-4-amine Chemical compound C1=CC=C2C(N)=CN=CC2=C1 ISIUXVGHQFJYHM-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- KBEMFSMODRNJHE-JFWOZONXSA-N lodenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@@H]1F KBEMFSMODRNJHE-JFWOZONXSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical class NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.逆転写酵素依存ウイルスの複製を阻害するための治療薬の製造に際しての、 デオキシリボヌクレオシド フォスフェートの菌体内のプールを減損させる化合 物の使用。 2.前記ウイルスがレトロウイルスである、請求項1記載の使用。 3.前記したデオキシヌクレオシド フォスフェートを減損させる化合物が、デ オキシヌクレオチドの合成の阻害剤である、請求項1記載の使用。 4.前記したデオキシヌクレオシド フォスフェートを減損させる化合物が、リ ボヌクレオチド リダクターゼの阻害剤である、請求項1記載の使用。 5.前記化合物がヒドロキシウレアである、請求項4記載の使用。 6.前記ウイルスがヒト免疫不全ウイルス(HIV)である、請求項1記載の使 用。 7.前記治療薬が、抗ウイルスヌクレオシド フォスフェート類縁体をも含有し ている、請求項1記載の使用。 8.前記治療薬が、DNAの鎖伸長反応を終結させることによって前記ウイルス の複製を阻害するように働く化合物をも含有している、請求項1記載の使用。 9.DNAの鎖伸長反応を終結させることによって前記ウイルスの複製を阻害す るように働く前記の化合物が、ウイルスDNAの合成を未熟なうちに終結させる ことで複製を阻害し、不完全なウイルスDNAを生じさせる、請求項8記載の使 用。 10.前記した第二の化合物がジデオキシヌクレオシドまたはAZTである、請求 項8記載の使用。 11.前記のジデオキシヌクレオシドが2’−フルオロプリンジデオキシヌクレオ シドである、請求項10記載の使用。 12.前記のジデオキシヌクレオシドが、次の化合物:ddl、ddC、2’−F −dd−ara−A、2’−F−dd−ara−Iまたは2’−F−dd−ar a−Gのうちの一種である、請求項11記載の使用。 13.動物細胞中の逆転写酵素依存ウイルスから不完全なウイルスDNAを生じさ せる方法であって、この細胞に対して、デオキシリボヌクレオシド フォスフェ ートの菌体内のプールを減損させる化合物を、前記ウイルスの複製を阻害するの に有効な量、投与する工程を有している方法。 14.動物細胞中の逆転写酵素依存ウイルスの複製を阻害する方法であって、この 細胞に対して、デオキシリボヌクレオシド フォスフェートの菌体内のプールを 減損させる化合物を、前記ウイルスの複製を阻害するのに有効な量、投与する工 程を有している方法。 15.前記ウイルスがレトロウイルスである、請求項14記載の方法。 16.前記したデオキシヌクレオシド フォスフェートを減損させる化合物が、デ オキシヌクレオチドの合成の阻害剤である、請求項14記載の方法。 17.前記したデオキシヌクレオシド フォスフェートを減損させる化合物が、リ ボヌクレオチド リダクターゼの阻害剤である、請求項14記載の方法。 18.前記化合物がヒドロキシウレアである、請求項17記載の方法。 19.前記細胞がインビトロである、請求項14記載の方法。 20.前記動物細胞が哺乳類の細胞である、請求項14記載の方法。 21.前記ウイルスがヒト免疫不全ウイルスであり、前記細胞がヒト細胞である、 請求項14記載の方法。 22.動物細胞中の逆転写酵素依存ウイルスの複製を阻害する方法であって、抗ウ イルス性のヌクレオシド フォスフェート類縁体の前記細胞への投与と関連して 、デオキシリボヌクレオシド フォスフェートの菌体内のプールを減損させる化 合物を前記細胞へと投与する工程を含んでいる方法。 23.前記したデオキシヌクレオチド フォスフェートを減損させる化合物が、リ ボヌクレオチド リダクターゼの阻害剤である、請求項22記載の方法。 24.前記化合物がヒドロキシウレアである、請求項23記載の方法。 25.動物細胞中の逆転写酵素依存ウイルスの複製を阻害する方法であって、デオ キシリボヌクレオシド フォスフェートの菌体内のプールを減損させる第一の化 合物を前記細胞へと投与するのに際して、DNAの鎖伸長反応を終結させること によって前記ウイルスの複製を阻害するように働く第二の化合物と関連して投与 する工程を含んでいる方法。 26.前記第二の化合物が、ウイルスDNAの合成を未熟なうちに終結させること で複製を阻害し、不完全なウイルスDNAを生じさせる、請求項25記載の方法 。 27.前記第一の化合物が、リボヌクレオチド リダクターゼの阻害剤である、請 求項25記載の方法。 28.前記第一の化合物がヒドロキシウレアである、請求項27記載の方法。 29.前記第二の化合物が、ジデオキシヌクレオシドおよびAZTからなる群より 選択されている、請求項25記載の方法。 30.前記ジデオキシヌクレオシドが、2’−フルオロプリンジデオキシヌクレオ シドである、請求項29記載の方法。 31.前記ジデオキシヌクレオシドが、ddl、ddC、2’−F−dd−ara −A、2’−F−dd−ara−Iおよび2’−F−dd−ara−Gからなる 群より選択されている、請求項29記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6581493A | 1993-05-21 | 1993-05-21 | |
US08/065,814 | 1993-05-21 | ||
PCT/US1994/005515 WO1994027590A1 (en) | 1993-05-21 | 1994-05-17 | New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005375358A Division JP2006143743A (ja) | 1993-05-21 | 2005-12-27 | デオキシヌクレオチド合成の阻害剤を使用することによって逆転写酵素依存ウイルスの複製を阻害する新規な組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08509957A true JPH08509957A (ja) | 1996-10-22 |
JP4117901B2 JP4117901B2 (ja) | 2008-07-16 |
Family
ID=22065285
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51846694A Expired - Fee Related JP4117901B2 (ja) | 1993-05-21 | 1994-05-17 | デオキシヌクレオチド合成の阻害剤を使用することによって逆転写酵素依存ウイルスの複製を阻害する新規な方法 |
JP2005375358A Pending JP2006143743A (ja) | 1993-05-21 | 2005-12-27 | デオキシヌクレオチド合成の阻害剤を使用することによって逆転写酵素依存ウイルスの複製を阻害する新規な組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005375358A Pending JP2006143743A (ja) | 1993-05-21 | 2005-12-27 | デオキシヌクレオチド合成の阻害剤を使用することによって逆転写酵素依存ウイルスの複製を阻害する新規な組成物 |
Country Status (8)
Country | Link |
---|---|
US (5) | US6046175A (ja) |
EP (1) | EP0706387B1 (ja) |
JP (2) | JP4117901B2 (ja) |
AT (1) | ATE273700T1 (ja) |
AU (1) | AU685128B2 (ja) |
CA (1) | CA2163456C (ja) |
DE (1) | DE69433953T2 (ja) |
WO (1) | WO1994027590A1 (ja) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728575A (en) * | 1990-02-01 | 1998-03-17 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
SE9003151D0 (sv) * | 1990-10-02 | 1990-10-02 | Medivir Ab | Nucleoside derivatives |
EP0610444B1 (en) | 1991-10-31 | 2003-01-29 | ELFORD, Howard L. | Use of a polyhydroxybenzamide or a derivative thereof in the manufacture of a medicament for treating viral infectious diseases |
US6046175A (en) * | 1993-05-21 | 2000-04-04 | The United States Of America As Represented By The Department Of Health And Human Services | Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis |
US6093702A (en) * | 1993-12-20 | 2000-07-25 | The United States Of America As Represented By The Department Of Health And Human Services | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread |
US5521161A (en) * | 1993-12-20 | 1996-05-28 | Compagnie De Developpment Aguettant S.A. | Method of treating HIV in humans by administration of ddI and hydroxycarbamide |
US5703058A (en) | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US5705522A (en) * | 1995-09-15 | 1998-01-06 | Compagnie De Developpement Aguettant S.A. | Compounds having anti-inflammatory and anti-viral activity, compositions of these, alone and in combination with reverse transcriptase inhibitors |
CA2189097A1 (en) | 1995-11-15 | 1997-05-16 | Pin-Fang Lin | Composition and method of treating retroviral infection |
US5719132A (en) * | 1996-06-27 | 1998-02-17 | Bristol-Myers Squibb Company | Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil |
US6686462B2 (en) * | 1997-02-28 | 2004-02-03 | The Regents Of The University Of California | Antiviral compounds and methods of administration |
US6114312A (en) * | 1997-03-07 | 2000-09-05 | Research Institute For Genetic And Human Therapy (R.I.G.H.T.) | Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor |
US20020022034A1 (en) * | 1997-09-15 | 2002-02-21 | Julianna Lisziewicz | Therapeutic DNA vaccination |
AU6761198A (en) * | 1998-03-17 | 1999-10-11 | Julianna Lisziwiewicz | Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor |
US6251874B1 (en) * | 1998-03-26 | 2001-06-26 | Research Institute For Genetic And Human Therapy (R.I.G.H.T.) | Method of inhibiting human immunodeficiency virus using hydroxurea and a reverse transcriptase inhibitor in vivo |
WO2000045844A1 (en) * | 1999-02-03 | 2000-08-10 | Franco Lori | Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv |
US20050124566A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
US20050196767A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA) |
EP3231445A1 (en) * | 2001-05-18 | 2017-10-18 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20050203040A1 (en) * | 2001-05-18 | 2005-09-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) |
US20050233997A1 (en) * | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
US20050159382A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA) |
US20050288242A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA) |
US20050196765A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US20050159381A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA) |
US20050158735A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7151092B2 (en) | 2002-10-31 | 2006-12-19 | Metabasis Therapeutics, Inc. | Cytarabine monophosphate prodrugs |
CN101088557A (zh) | 2006-06-12 | 2007-12-19 | 天津市扶素生物技术有限公司 | 用于预防或治疗hiv感染的药用组合物及其应用 |
EP2269100A4 (en) * | 2008-04-23 | 2011-12-28 | Ravenbrick Llc | HANDLING OF GLOSSY ON REFLECTIVE AND THERMO-THINKING SURFACES |
US20090317466A1 (en) * | 2008-06-18 | 2009-12-24 | Franco Lori | Fixed dose pharmaceutical composition comprising hyroxyurea and didanosine |
US9011817B2 (en) * | 2009-09-03 | 2015-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and methods of making compounds |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
AU2015217221A1 (en) | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
EP3164136A4 (en) | 2014-07-02 | 2018-04-04 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
WO2018187479A1 (en) * | 2017-04-04 | 2018-10-11 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
AU2019207625A1 (en) | 2018-01-09 | 2020-07-30 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
GB202111184D0 (en) * | 2021-08-03 | 2021-09-15 | Hendriks Gerardus Johannes | Methods |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8324800D0 (en) * | 1983-09-15 | 1983-10-19 | Pasteur Institut | Antigens |
AU591125B2 (en) * | 1985-05-15 | 1989-11-30 | Wellcome Foundation Limited, The | Therapeutic nucleosides |
WO1987001284A1 (en) * | 1985-08-26 | 1987-03-12 | United States Of America, Represented By The Unite | Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine |
IL77496A (en) * | 1986-01-01 | 1989-02-28 | Univ Ramot | Anti-viral preparations comprising isatine 3-thiosemicarbazones |
US5110600A (en) * | 1988-01-25 | 1992-05-05 | The Regents Of The University Of California | Method of treating viral infections with amino acid analogs |
US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
AU9125191A (en) * | 1990-11-19 | 1992-06-11 | Monsanto Company | Retroviral protease inhibitors |
EP0610444B1 (en) * | 1991-10-31 | 2003-01-29 | ELFORD, Howard L. | Use of a polyhydroxybenzamide or a derivative thereof in the manufacture of a medicament for treating viral infectious diseases |
US5300059A (en) * | 1991-11-19 | 1994-04-05 | Hydro Slip Technologies Inc. | Bloodbag and method of making same |
AU4253193A (en) * | 1992-05-20 | 1993-12-13 | G.D. Searle & Co. | Urea-containing hydroxyethylamine compounds as retroviral protease inhibitors |
US6046175A (en) * | 1993-05-21 | 2000-04-04 | The United States Of America As Represented By The Department Of Health And Human Services | Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis |
US6093702A (en) | 1993-12-20 | 2000-07-25 | The United States Of America As Represented By The Department Of Health And Human Services | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread |
US5521161A (en) * | 1993-12-20 | 1996-05-28 | Compagnie De Developpment Aguettant S.A. | Method of treating HIV in humans by administration of ddI and hydroxycarbamide |
-
1994
- 1994-05-17 US US08/245,259 patent/US6046175A/en not_active Expired - Fee Related
- 1994-05-17 EP EP94918016A patent/EP0706387B1/en not_active Expired - Lifetime
- 1994-05-17 AT AT94918016T patent/ATE273700T1/de not_active IP Right Cessation
- 1994-05-17 WO PCT/US1994/005515 patent/WO1994027590A1/en active IP Right Grant
- 1994-05-17 AU AU69519/94A patent/AU685128B2/en not_active Ceased
- 1994-05-17 JP JP51846694A patent/JP4117901B2/ja not_active Expired - Fee Related
- 1994-05-17 DE DE69433953T patent/DE69433953T2/de not_active Expired - Lifetime
- 1994-05-17 CA CA002163456A patent/CA2163456C/en not_active Expired - Fee Related
-
2000
- 2000-02-03 US US09/497,700 patent/US6194390B1/en not_active Expired - Fee Related
-
2001
- 2001-01-08 US US09/756,411 patent/US20010008905A1/en not_active Abandoned
-
2005
- 2005-10-14 US US11/250,899 patent/US20060052317A1/en not_active Abandoned
- 2005-12-27 JP JP2005375358A patent/JP2006143743A/ja active Pending
-
2006
- 2006-03-08 US US11/371,116 patent/US20060154892A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060154892A1 (en) | 2006-07-13 |
AU6951994A (en) | 1994-12-20 |
US20060052317A1 (en) | 2006-03-09 |
AU685128B2 (en) | 1998-01-15 |
US6194390B1 (en) | 2001-02-27 |
EP0706387B1 (en) | 2004-08-18 |
CA2163456A1 (en) | 1994-12-08 |
US20010008905A1 (en) | 2001-07-19 |
CA2163456C (en) | 2009-06-23 |
EP0706387A1 (en) | 1996-04-17 |
WO1994027590A1 (en) | 1994-12-08 |
DE69433953T2 (de) | 2005-08-25 |
JP4117901B2 (ja) | 2008-07-16 |
JP2006143743A (ja) | 2006-06-08 |
DE69433953D1 (de) | 2004-09-23 |
ATE273700T1 (de) | 2004-09-15 |
US6046175A (en) | 2000-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4117901B2 (ja) | デオキシヌクレオチド合成の阻害剤を使用することによって逆転写酵素依存ウイルスの複製を阻害する新規な方法 | |
EP0286224B1 (en) | Treatment of human viral infection by dsrna combined with viral inhibitors | |
Gao et al. | Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. | |
Enzo et al. | HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587 | |
CN1943782A (zh) | 治疗禽流感感染 | |
JP7475702B2 (ja) | 筋痛性脳脊髄炎患者における運動耐容能を改善する方法 | |
Broder | Pharmacodynamics of 2′, 3′-dideoxycytidine: an inhibitor of human immunodeficiency virus | |
Merigan | Treatment of AIDS with combinations of antiretroviral agents | |
JPH05507481A (ja) | ウイルス性肝炎の診断及び治療 | |
Lori et al. | Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug | |
JPS61500224A (ja) | 腫瘍性組織を放射線に対して増感する医薬組成物 | |
Mayhew et al. | Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea | |
Hentosh et al. | 2-Chloro-2′-deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function | |
WO1999048504A1 (en) | Compositions for inhibiting human immunodeficiency virus using hydroxyurea and a reverse transcriptase inhibitor | |
RU2021810C1 (ru) | Способ воздействия на развитие заболевания, вызванного hiv-вирусом или вирусом, вызывающим сходную биохимическую или клиническую картину | |
WO1999048526A1 (en) | METHOD OF RENDERING A HUMAN IMMUNODEFICIENCY VIRUS POPULATION REPLICATION INCOMPETENT $i(IN VIVO) | |
JP2002544147A (ja) | 伸張を阻害しない逆転写反応基質として許容されるヌクレオチド類似体の取り込みと重合による逆転写酵素の忠実度と達成度の制御法 | |
Balzarini et al. | Principles of antiretroviral therapy for AIDS and related diseases | |
WO1999047146A1 (en) | Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor | |
Santelli | Biochemical modulation of 5-fluorouracil with pyrimidines, purines and their nucleosides | |
CN1017653B (zh) | 用作病毒感染标记的活化核糖核酸酶l | |
US20020055470A1 (en) | Circumvention of human tumor drug resistance | |
WO1998031375A1 (en) | Enhanced suppression of hiv-1 by the combination of cytidine nucleoside analogues and ctp synthase inhibitors | |
US20130303479A1 (en) | Antiretroviral Cyclonucleoside Compositions and Methods and Articles of Title of Invention Manufacture Therewith | |
WO1998031375A9 (en) | Enhanced suppression of hiv-1 by the combination of cytidine nucleoside analogues and ctp synthase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041005 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050105 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050404 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060208 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060323 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20060330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080312 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080422 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110502 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |